Retractable Technologies Inc. announced today that it has entered into an amendment to the Technology Investment Agreement with the U.S. government providing $27,365,232 in additional funding. The. | May 25, 2021
Share this article
Share this article
PLYMOUTH MEETING, Pa., May 17, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the appointment of Roger D. Dansey, M.D. to its Board of Directors. The appointment adds extensive expertise in drug development to the INOVIO Board as the company strengthens its focus on its late stage product development programs. Currently the Chief Medical Officer at Seagen (formerly Seattle Genetics), Dr. Dansey has played a central role in Seagen s efforts to become a globally recognized, multi product oncology company.
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from.
E-Mail
IMAGE: A miniature ultrasound device (inset) is placed directly over a patient s spleen, directing low-intensity sound waves at the organ to potentially reduce severe inflammation associated with COVID-19 infection.. view more
Credit: Photo courtesy of SecondWave Systems.
Researchers at University of California San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays. It s a pilot study to evaluate whether ultrasound stimulation focused on the spleen can reduce inflammatory biomarkers in hospital patients infected with SARS-CoV-2, said Imanuel Lerman, MD, associate professor of anesthesiology at UC San Diego School of Medicine and an affiliate of Qualcomm Institute at UC San Diego, where his lab is based. This will allow us to determine whether treating patients this way can really affect clinical outcomes